Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVBP ArriVent BioPharma	$20.11 +1.2%	$20.99	$15.47 ▼ $36.37	$815.84M	1.17	286,649 shs	297,405 shs
BGM BGM Group	$7.82 +3.9%	$9.82	$5.47 ▼ $17.17	$779.72M	1.26	65,408 shs	4,594 shs
HRTX Heron Therapeutics	$1.40 +6.1%	$1.86	$1.04 ▼ $2.68	$214.61M	1.15	2.33 million shs	3.51 million shs
OCS Oculis	$17.85 +0.3%	$18.38	$11.56 ▼ $23.08	$779.37M	0.27	11,396 shs	17,831 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVBP ArriVent BioPharma	0.00%	+2.97%	-6.25%	-1.42%	-15.93%
BGM BGM Group	0.00%	+3.24%	-28.63%	-46.69%	+33.59%
HRTX Heron Therapeutics	0.00%	+5.26%	-26.32%	-24.32%	-29.29%
OCS Oculis	0.00%	-0.28%	+1.13%	-6.10%	+49.50%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVBP ArriVent BioPharma	2.5067 of 5 stars	4.5	0.0	0.0	0.0	3.6	0.8	0.0
BGM BGM Group	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
HRTX Heron Therapeutics	4.2069 of 5 stars	3.2	1.0	0.0	4.2	3.5	3.3	0.6
OCS Oculis	2.9967 of 5 stars	3.5	5.0	0.0	0.0	2.9	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVBP ArriVent BioPharma	3.00	Buy	$39.14	94.64% Upside
BGM BGM Group	0.00	N/A	N/A	N/A
HRTX Heron Therapeutics	2.33	Hold	$4.50	221.43% Upside
OCS Oculis	3.00	Buy	$35.67	99.81% Upside

Current Analyst Ratings Breakdown

Latest HRTX, BGM, OCS, and AVBP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/22/2025	OCS Oculis	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$32.00 ➝ $33.00
8/18/2025	AVBP ArriVent BioPharma	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/12/2025	AVBP ArriVent BioPharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $42.00
8/12/2025	AVBP ArriVent BioPharma	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $33.00
8/12/2025	HRTX Heron Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell
8/8/2025	HRTX Heron Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$4.00 ➝ $3.00
7/22/2025	AVBP ArriVent BioPharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00
7/10/2025	AVBP ArriVent BioPharma	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$33.00
6/24/2025	AVBP ArriVent BioPharma	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$39.00 ➝ $44.00
6/24/2025	AVBP ArriVent BioPharma	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$45.00
6/9/2025	HRTX Heron Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$6.00

(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVBP ArriVent BioPharma	N/A	N/A	N/A	N/A	$6.16 per share	N/A
BGM BGM Group	$25.10M	30.27	N/A	N/A	$7.34 per share	1.06
HRTX Heron Therapeutics	$149.69M	1.43	N/A	N/A	($0.18) per share	-7.78
OCS Oculis	N/A	N/A	N/A	N/A	$1.91 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVBP ArriVent BioPharma	-$80.49M	-$4.02	N/A	N/A	N/A	N/A	-55.40%	-51.97%	N/A
BGM BGM Group	-$1.44M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
HRTX Heron Therapeutics	-$13.58M	-$0.02	N/A	N/A	N/A	-0.62%	N/A	-0.40%	11/11/2025 (Estimated)
OCS Oculis	-$97.43M	-$2.67	N/A	N/A	N/A	-13,958.12%	-99.12%	-72.89%	11/6/2025 (Estimated)

Latest HRTX, BGM, OCS, and AVBP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/21/2025	Q2 2025	OCS Oculis	-$0.53	-$0.59	-$0.06	-$0.59	$0.14 million	$0.25 million
8/11/2025	Q2 2025	AVBP ArriVent BioPharma	-$0.70	-$0.90	-$0.20	-$0.90	N/A	N/A
8/8/2025	Q2 2025	HRTX Heron Therapeutics	-$0.01	-$0.02	-$0.01	-$0.02	$38.08 million	$37.20 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVBP ArriVent BioPharma	N/A	N/A	N/A	N/A	N/A
BGM BGM Group	N/A	N/A	N/A	N/A	N/A
HRTX Heron Therapeutics	N/A	N/A	N/A	N/A	N/A
OCS Oculis	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVBP ArriVent BioPharma	N/A	12.74	12.74
BGM BGM Group	N/A	1.82	1.45
HRTX Heron Therapeutics	N/A	0.82	0.53
OCS Oculis	N/A	4.79	4.79

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVBP ArriVent BioPharma	9.48%
BGM BGM Group	N/A
HRTX Heron Therapeutics	80.01%
OCS Oculis	22.30%

Insider Ownership

Company	Insider Ownership
AVBP ArriVent BioPharma	18.58%
BGM BGM Group	58.66%
HRTX Heron Therapeutics	5.86%
OCS Oculis	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVBP ArriVent BioPharma	40	40.57 million	33.03 million	N/A
BGM BGM Group	298	97.22 million	40.19 million	N/A
HRTX Heron Therapeutics	300	153.29 million	144.31 million	Optionable
OCS Oculis	2	43.66 million	N/A	Not Optionable

HRTX, BGM, OCS, and AVBP Headlines

Recent News About These Companies

Oculis (NASDAQ:OCS) Releases Quarterly Earnings Results, Misses Estimates By $0.06 EPS

August 24 at 8:28 AM | marketbeat.com

Oculis (NASDAQ:OCS) Price Target Raised to $33.00

August 24 at 8:19 AM | marketbeat.com

Oculis reports Q2 EPS (49c), consensus (43c)

August 23 at 8:40 AM | msn.com

Oculis Holding AG: Oculis Reports Q2 2025 Financial Results and Provides Company Update

August 22 at 10:28 AM | finanznachrichten.de

Oculis price target raised to $33 from $32 at H.C. Wainwright

August 22 at 10:28 AM | msn.com

Oculis Holding Reports Strong Financial Position in Mid-2025

August 22 at 10:28 AM | msn.com

Oculis Holding AG Reports Q2 2025 Financial Progress

August 21 at 12:10 AM | tipranks.com

Oculis Holding AG (OCS) Reports Q2 Loss, Beats Revenue Estimates

August 21 at 6:16 PM | zacks.com

Oculis Reports Q2 2025 Financial Results and Provides Company Update

August 21 at 4:05 PM | globenewswire.com

Oculis Reports Q2 2025 Financial Results and Provides Company Update

August 21 at 4:05 PM | globenewswire.com

Uncovering Potential: Oculis Holding's Earnings Preview

August 20, 2025 | benzinga.com

Aberdeen Group plc Boosts Stake in Oculis Holding AG $OCS

August 20, 2025 | marketbeat.com

Oculis (OCS) Expected to Announce Quarterly Earnings on Tuesday

August 20, 2025 | marketbeat.com

Oculis (OCS) to Release Quarterly Earnings on Thursday

August 20, 2025 | americanbankingnews.com

322,500 Shares in Oculis Holding AG (NASDAQ:OCS) Purchased by SR One Capital Management LP

August 19, 2025 | marketbeat.com

Oculis Holding AG (NASDAQ:OCS) Short Interest Down 54.1% in July

August 19, 2025 | marketbeat.com

Privosegtor shows functional, anatomical improvements in patients with optic neuritis

August 12, 2025 | healio.comH

Oculis Holding AG to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

August 12, 2025 | quiverquant.comQ

Oculis to Participate in Upcoming H.C Wainwright 5th Annual Ophthalmology Virtual Conference

August 12, 2025 | globenewswire.com

Oculis to Participate in Upcoming H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

August 12, 2025 | globenewswire.com

Oculis Holding AG Secures Amended Loan Agreement with Kreos Capital

August 2, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

HRTX, BGM, OCS, and AVBP Company Descriptions

ArriVent BioPharma NASDAQ:AVBP

$20.11 +0.23 (+1.16%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$19.95 -0.16 (-0.79%)

As of 08/22/2025 05:01 PM Eastern

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

BGM Group NASDAQ:BGM

$7.82 +0.30 (+3.92%)

Closing price 08/22/2025 03:57 PM Eastern

Extended Trading

$7.94 +0.12 (+1.59%)

As of 08/22/2025 04:31 PM Eastern

Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. Qilian International Holding Group Limited was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.

Heron Therapeutics NASDAQ:HRTX

$1.40 +0.08 (+6.06%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.44 +0.04 (+2.79%)

As of 08/22/2025 07:07 PM Eastern

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Oculis NASDAQ:OCS

$17.85 +0.05 (+0.28%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$17.84 -0.02 (-0.08%)

As of 08/22/2025 04:04 PM Eastern

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time